Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis

Table 2 Costs, QALY and net monetary benefit results from base case 4-year time horizon

	Combination therapy	5-ARI	α-blockers	FT
	Combination therapy	5-ARI	α-blockers	Price $14,000	Price $5000
Costs per patient ($)	1308.58	1566.35	1431.41	14,831.46	5864.82
QALY per patient	1.87	1.87	1.87	1.96	1.96
Willingness-to-pay threshold at $150,000
Net Monetary Benefit (NMB) ($)	279,191.42	278,633.65	279,068.59	279,168.54	288,135.18
Willingness-to-pay threshold at $50,000
Net Monetary Benefit (NMB) ($)	92,191.42	91,833.65	92,068.59	83,168.54	92,135.18

QALY Quality-adjusted life years, 5-ARI 5-α-Reductase inhibitors, FT Fexapotide triflutate

ISSN: 1471-2490